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A B S T R A C T
Background
Bronchiectasis is increasingly recognized as a major cause of respiratory morbidity especially in developing countries and in some ethnic
populations of affluent countries. It is characterized by irreversible dilatation of airways, generally associated with chronic bacterial
infection. Medical management largely aims to reduce morbidity by controlling the symptoms and by preventing the progression of
bronchiectasis.
Objectives
To evaluate the efficacy of inhaled corticosteroids (ICS) in children and adults with bronchiectasis (a) during stable bronchiectasis; and
for reducing; (b) the severity and frequency of acute respiratory exacerbations and (c) long term pulmonary decline.
Search methods
The Cochrane Register of Controlled Trials (CENTRAL), the Cochrane Airways Group Specialized Register of trials, MEDLINE and
EMBASE databases were searched by the Cochrane Airways Group. The latest searches were performed in October 2010.
Selection criteria
All randomised controlled trials comparing ICS with a placebo or no medication. Children and adults with clinical or radiographic
evidence of bronchiectasis were included, but patients with cystic fibrosis (CF) were excluded.
Data collection and analysis
Results of searches were reviewed against pre-determined criteria for inclusion.
Main results
There were no paediatric studies. Six adult studies fulfilled the inclusion criteria. Of the 303 randomised, 278 subjects completed the
trials. In the short term group (ICS for less then 6 months duration), adults on huge doses of ICS (2g per day of budesonide equivalent)
had significantly improved forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), Quality of life (QOL)
score and sputum volume but no significant difference in peak flow, exacerbations, cough or wheeze, when compared to adults in the
control arm (no ICS). When only placebo-controlled studies were included, there were no significant difference between groups in all
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outcomes examined (spirometry, clinical outcomes of exacerbation or sputum volume etc). The single study on long term outcomes
showed no significant effect of inhaled steroids in any of the outcomes.
Authors’ conclusions
The present review indicates that there is insufficient evidence to recommend the routine use of inhaled steroids in adults with stable
state bronchiectasis. While a therapeutic trial may be justified in adults with difficult to control symptoms and in certain subgroups,
this has to be balanced with adverse events especially if high doses are used. No recommendation can be made for the use of ICS in
adults during an acute exacerbation or in children (for any state) as there were no studies.
P L A I N L A N G U A G E S U M M A R Y
Role of inhaled corticosteroids in management of non CF bronchiectasis
People with bronchiectasis have significant morbidity (e.g. cough, wheeze, sputum production) and have more rapid lung function
decline. As asthma like symptoms are common in people with bronchiectasis, the routine use of inhaled corticosteroids is potentially
beneficial in reducing exacerbations, symptoms and pulmonary decline. The review found that there is insufficient evidence for the
routine use of inhaled corticosteroids in people with bronchiectasis. While inhaled corticosteroids may be beneficial in a subgroup of
people with bronchiectasis, its use has to be balanced with adverse effects that include potential increase in commensal bacterial density
in the sputum.
B A C K G R O U N D
Bronchiectasis, previously termed an ’orphan disease’ is increas-
ingly recognized as a major cause of respiratory morbidity es-
pecially in developing countries (Karadag 2005, Karakoc 2001)
and in some ethnic populations of affluent countries (Chang
2002, Edwards 2003, Singleton 2000). The underlying aetiology
of bronchiectasis varies from post recurrent respiratory infections
to rare immune deficiencies. Other causes include primary cil-
iary dyskinesia, allergic bronchopulmonary aspergillosis and My-
cobacterial infection (Shoemark 2007). However, bronchiectasis
is also a common pathway for a variety of diseases. Thus, the pres-
ence of bronchiectasis is also increasingly recognised in common
(e.g. chronic obstructive pulmonary disease (COPD) (Patel 2004,
O’Brien 2000) and uncommon respiratory diseases (e.g. bronchi-
olitis obliterans (Chang 1998) and sarcoidosis (Lewis 2002)) as
well non primary respiratory (e.g. autoimmune) diseases. When
bronchiectasis is present with another underlying disorder, it in-
creases the morbidity and mortality of the underlying diseases
(Lewis 2002,Keistinen1997). For example, in diseases likeCOPD
the presence of bronchiectasis has been reported in 29-50% (Patel
2004, O’Brien 2000) of cohorts and when present, increases the
severity (Patel 2004) and frequency (Gursel 2006) of respiratory
exacerbations. Thus, management of the symptoms and severity
of bronchiectasis is important.
The dominant symptoms and signs of bronchiectasis are produc-
tive or wet cough, dyspnoea on exertion and presence of other res-
piratory signs (clubbing, chest wall deformity, respiratory noises
such as wheeze or crepitations on auscultation). In the long term,
pulmonary decline may occur (Keistinen 1997, Twiss 2006). In
both children and adult cohort studies, asthma-like symptoms in
people with bronchiectasis have been described and when present,
is associated with accelerated pulmonary decline when compared
to those with bronchiectasis but without asthma-like symptoms
(Keistinen 1997, Field 1969).
Like patients with COPD, children and adults with bronchiecta-
sis also suffer from recurrent acute exacerbations, some of whom
require hospitalised treatment. Effective management regimes for
bronchiectasis would reduce the frequency or severity of respi-
ratory exacerbations, and/or the long term pulmonary decline.
Based on Cole’s ’vicious circle hypothesis’, microbial colonization/
infection is important in the pathophysiology of bronchiectasis
as it leads to bronchial obstruction and a normal or exaggerated
inflammatory response (Cole 1986). Neutrophilic airway inflam-
mation is dominant in people with bronchiectasis and COPD and
ICS is likely beneficial in people with COPD (Abramson 2006).
However use of ICS is associated with adverse events in children
and adults that range from mild (candidiasis) to serious (adrenal
insufficiency, osteoporosis, cataracts) events. Thus a systematic re-
view on the efficacy of ICS in the management of children and
adults with bronchiectasis would help guide clinical practice. This
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current review was significantly revised from a previous review
(Ram 2000).
O B J E C T I V E S
To evaluate the efficacy of inhaled corticosteroids (ICS) in children
and adults with bronchiectasis;
(a) during stable bronchiectasis;
and for reducing
(b) the severity and frequency of acute respiratory exacerbations
and
(c) long term pulmonary decline
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials using ICS in patients with
bronchiectasis.
Types of participants
Children or adults with bronchiectasis (defined clinically or radi-
ologically) not related to CF.
Exclusion criteria: Participants with cystic fibrosis.
Types of interventions
All types of ICS.
Types of outcome measures
It was planned that attempts would have beenmade to obtain data
on at least one of the following outcome measures:
(A) for short term effectiveness (6 months or less)
a) mean difference in bronchiectasis severity control (QOL, cough
diary, Likert scale, visual analogue scale, level of interference of
cough, cough diary, etc),
b) total numbers of days with respiratory symptoms
c)mean difference in lung function indices (spirometry, other lung
volumes, airway hyper-responsiveness)
d) participants who had respiratory exacerbations and/or hospi-
talisations,
e) total number of hospitalised days
f ) mean difference in other objective indices (airway markers of
inflammation, exhaled nitric oxide etc)
g) proportions experiencing adverse effects of the intervention,
(e.g. pharyngeal candidiasis, voice change, etc)
(B) for medium to long term outcomes (> 6 months)
h) radiology scores (high resolution computed tomography scans
or chest radiograph)
i) lung function
j) clinical indices of bronchiectasis severity control (QOL, cough
diary, Likert scale, visual analogue scale, level of interference of
cough, etc),
k) relevant airway markers of inflammation.
l) mortality
m) proportions experiencing adverse effects of the intervention,
(e.g. adrenal insufficiency, cataracts, linear growth etc)
Search methods for identification of studies
Trials were identified from the following sources:
1. The Cochrane Airways Group Specialized Trials Register
(updated October 2010)
2. The Cochrane Central Register of Controlled Trials
(CENTRAL): Issue 4, 2010
3. MEDLINE (1950 to October 2010).
4. EMBASE (1980 to October 2010).
5. The list of references in relevant publications.
6. Written communication with the authors of trials included
in the review when necessary.
For the full database topic search strategies see Appendix 1.
Data collection and analysis
Selection of studies
From the title, abstract, or descriptors, two reviewers (NK, AC)
independently reviewed the literature searches to identify poten-
tially relevant trials for full review. Searches of bibliographies and
texts were conducted to identify additional studies. From the full
text using specific criteria, the same two reviewers independently
selected trials for inclusion. Agreement was measured using kappa
statistics. Disagreement was resolved by consensus.
Data extraction and management
Trials that satisfied the inclusion criteria were reviewed and the fol-
lowing information recorded: study setting, year of study, source
of funding, patient recruitment details (including number of eli-
gible subjects), inclusion and exclusion criteria, other symptoms,
randomisation and allocation concealment method, numbers of
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participants randomised, blinding (masking) of participants, care
providers and outcome assessors, dose and type of intervention,
duration of therapy, co-interventions, numbers of patients not fol-
lowed up, reasons for withdrawals from study protocol (clinical,
side-effects, refusal and other), details on side-effects of therapy,
and whether intention-to-treat analyses were possible. Data were
extracted on the outcomes described previously. Further informa-
tion was requested from the authors but only two (Martinez 2006;
Joshi 2004) responded with limited further information.
Assessment of risk of bias in included studies
We assessed the risk of bias for each of the studies included in the
review independently (by two reviewers: NK & AC).
Four components of quality were assessed:
1. Allocation concealment. Trials were scored as: Adequate
concealment (low risk of bias); Unclear (unclear risk of bias);
clearly inadequate concealment (high risk of bias).
2. Blinding. Trials were scored as: Participant and care
provider and outcome assessor blinded and/or outcome assessor
blinded (low risk of bias); unclear (unclear risk of bias); no
blinding of outcome assessor (high risk of bias).
3. Reporting of participants by allocated group. Trials were
scored as: Progress of all randomised participants in each group
described (low risk of bias); Unclear or no mention of
withdrawals or dropouts (high risk of bias)
4. Follow-up. Trials were scored as: Outcomes measured in
>90% (where withdrawals due to complications and side-effects
are categorised as treatment failures, low risk of bias), Grade B:
Outcomes measured in 80-90%, Grade C: Unclear, Grade D:
Outcomes measured in <80%. (Grade A = high quality).
All assessments were included in Characteristics of included
studies. Inter-reviewer reliability for the identificationof high qual-
ity studies for each component was measured by the Kappa statis-
tic.
Data synthesis
For the dichotomous outcome variables of each individual study,
odds ratio (OR) was calculated using amodified intention-to-treat
analysis. This analysis assumes that participants not available for
outcome assessment have not improved (and probably represents a
conservative estimate of effect). An initial qualitative comparison
of all the individually analysed studies examined whether pooling
of results (meta-analysis) is reasonable. This took into account dif-
ferences in study populations, inclusion/exclusion criteria, inter-
ventions, outcome assessment, and estimated effect size.
Results from studies that met the inclusion criteria and reported
any of the outcomes of interest were included in the subsequent
meta-analyses. The summary weighted risk ratio and 95% confi-
dence interval (fixed effects model) were calculated (Cochrane sta-
tistical package, RevMan version 5). For cross-over studies, mean
treatment differences were calculated from raw data, extracted or
imputed and entered as fixed effects generic inverse variance (GIV)
outcome, to provide summary weighted differences and 95% con-
fidence intervals. In cross-over trials, only data from the first arm
were included inmeta-analysis when the data were combined with
parallel studies (Elbourne 2002).Numbers needed to treat (NNT)
were calculated from the pooled OR and its 95% CI applied to
a specified baseline risk using an online calculator (Cates 2003).
If studies reported outcomes using different measurement scales,
the standardised mean difference was used. Any heterogeneity be-
tween the study results was described and tested to see if it reached
statistical significance using a chi-squared test. The 95% confi-
dence interval estimated using a random effects model were in-
cluded whenever there are concerns about statistical heterogeneity.
Subgroup analysis and investigation of heterogeneity
The following a priori sub-group analysis was planned:
1. children (aged 18 years or less) and adults (>18 years)
2. dose of ICS; low (< 400 ug), moderate (400-800 ug), high
(>800 ug) of budesonide equivalent
3. participant type (bronchiectasis as primary disease versus
bronchiectasis as co-existent disease)
4. severity of bronchiectasis (based on lung function)
Sensitivity analysis
Sensitivity analyses were also planned to assess the impact of the
potentially important factors on the overall outcomes:
1. study quality;
2. variation in the inclusion criteria;
3. differences in the medications used in the intervention and
comparison groups;
4. differences in outcome measures;
5. analysis using random effects model;
6. analysis by “treatment received”; and
7. analysis by “intention-to-treat”.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
From the 2006 and 2007 searches, the Airways Group specialised
register/search identified 341 potentially relevant titles. After as-
sessing the abstracts, 9 paperswere obtained for consideration to be
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included into review. Three studies were excluded as ICS were not
compared to placebo/ no treatment or were non-randomised stud-
ies or included subjects with pneumonia (Ghosh 2002; Monton
1999; ONeil 2004) see Characteristics of excluded studies). The
searches from 2008-2010 identified a further 161 references, none
of which were eligible for inclusion.
Included studies
Six studies met the inclusion criteria (Elborn 1992; Joshi 2004;
Martinez 2006; Tsang 1998; Tsang 2004; Tsang 2005), all were
uni-centre studies. The studies included patients with bronchiec-
tasis diagnosed on bronchography (Elborn 1992) or high resolu-
tion CT (HRCT) of the chest (Joshi 2004; Martinez 2006; Tsang
1998; Tsang 2004; Tsang 2005). All studies excluded patients with
CF with Joshi 2004;Martinez 2006; Tsang 1998; Tsang 2004 and
Tsang 2005 excluding patients with bronchial asthma as well. Pa-
tients with allergic bronchopulmonary aspergillosis (ABPA) were
also excluded from Elborn 1992 and Martinez 2006. No study
was conducted in children. All studies were published in English.
Joshi 2004 and Elborn 1992 were cross over studies and the others
were parallel group studies. All were double blind placebo con-
trolled trials except Martinez 2006 which did not use placebo in
the control group.
Patients with bronchiectasis were recruited during stable state de-
fined as free from exacerbation for 4 weeks (Joshi 2004; Martinez
2006) or stable 24 hour sputum volume, FEV1 and FVC (Tsang
1998; Tsang 2004; Tsang 2005). No study was performed in acute
respiratory exacerbation.
Moderate to high doses of inhaled steroids were used: beclometha-
sone 800 µg/ day (Joshi 2004), beclomethasone 1500 µg/day
in Elborn 1992 and fluticasone 1000 µg/day (2000ug/day BDP
equivalent) (Martinez 2006; Tsang 1998; Tsang 2004; Tsang
2005). Martinez 2006 had a third arm with inhaled fluticasone
500 mcg/day but that data was not included in the final primary
analyses to have uniformity of steroid dose with the other included
studies (Tsang 1998; Tsang 2004; Tsang 2005). The results from
the lower dose arm was included in the sensitivity analyses.
The study duration ranged from a short duration of 4-6 weeks
(Joshi 2004; Tsang 1998; Elborn 1992) to 6 months in Martinez
2006 with visits at 1, 3 and 6 months. Two studies were of one
year duration (Tsang 2004; Tsang 2005) with visits at 4, 12, 24,
36 and 52 weeks . Additional data were requested from all authors
but only 2 authors (Joshi 2004; Martinez 2006) responded and
provided additional data. Data on outcomes at 24 weeks for Tsang
2005 as well as the lung function values in actual volumes (instead
of % predicted) was also requested from the authors.
Lung functions were included as an outcome variable in all studies
except Tsang 2004 which reported only FeNO levels. FEV1 and
FVC (in litres or % predicted) were available from all studies.
PEFR were reported by Elborn 1992; Joshi 2004 and Tsang 1998
with Martinez 2006 and Tsang 1998 giving details about TLC,
RV and diffusion capacity.
Clinical parameters of cough,wheeze anddyspnoeaweremeasured
differently in different studies. Elborn 1992 used a visual analogue
scale to quantify these symptoms, Martinez 2006 defined signifi-
cant cough as that persisting for > 50% of days. Dyspnea was mea-
sured by using the transition dyspnoea index by Martinez 2006.
Clinical parameters of cough, dyspnoea and wheezing though re-
ported by Tsang 2005 were not defined properly and were not
included in the analysis. 24 hour sputum volume was included as
a outcome variable in Elborn 1992; Martinez 2006; Tsang 1998
and Tsang 2005
Quality of life was included as an outcome parameter byMartinez
2006 and it used the Spanish version of the St. George Respiratory
Questionnaire (SGRQ) to calculate total scores as well as symp-
toms, activity and impact score.
All studies which had exacerbation as an outcome variable
(Martinez 2006; Tsang 1998 ; Tsang 2005) defined exacerbation
as persistent (>24hours) deterioration in at least three respiratory
symptoms (including cough, dyspnoea, haemoptysis, increased
sputum purulence or volume, and chest pain), with or without
fever, radiographic deterioration, systemic disturbances, or deteri-
oration in chest signs.
Risk of bias in included studies
Allocation concealment was unclear in all 6 studies (Elborn 1992;
Joshi 2004; Martinez 2006; Tsang 1998; Tsang 2004; Tsang
2005). All studies were double blind studies exceptMartinez 2006
which did not have a placebo arm and blinding was done only for
comparing two dosages of ICS. The baseline values for lung func-
tions, sputum amount and sputum inflammatory markers were
significantly different clinically in Tsang 1998 and thus were sub-
ject to bias. Four studies (Martinez 2006; Tsang 1998; Tsang 2004;
Tsang 2005) reported the progress of all randomised subjects in
each group described whereas in Joshi 2004 there was no mention
of withdrawals or dropouts. As the pre crossover arm data could
not be extracted, data from Elborn 1992 could not be included in
any of the meta-analysis. The follow up was between 80-90% in
Tsang 2005 and was unclear in Joshi 2004. The remaining studies
(Martinez 2006; Tsang 1998; Tsang 2004) reported outcomes in
> 90% of the subjects. The agreement between the two authors
was excellent (weighted kappa score for quality assessment scores
was 0.81).
Inclusion of only those patients who had a significant post bron-
chodilator response in Joshi 2004 biased the study in favour of
response to ICS since those with positive bronchodilator response
are more likely to improve with ICS due to the asthma like re-
versibility in their airway.
Effects of interventions
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The 6 trials (Elborn1992; Joshi 2004;Martinez 2006;Tsang 1998;
Tsang 2004 and Tsang 2005) involved 303 participants with 278
completing the studies. Data that could be included in the meta-
analysis were very limited.
Stable state short term (< 6 months) outcomes
(Comparison 1)
Data from Joshi 2004; Martinez 2006; Tsang 1998 and Tsang
2004 were included in the short term stable state analysis.
1. Clinical severity indices (Outcome 1.1, Figure 1): Only data
from a single study (Martinez 2006 which was a non-placebo
study) could be displayed for these clinical parameters. Using ITT
analysis, the number of subjects without sputum reduction as
well as without improvement in dyspnoea (comparison 1.1.3 and
1.1.4) were significantly more in the control arm compared to the
ICS arm. Subjects in the ICS group were significantly better than
the control arm in the parameters of sputum volume reduction
(OR of 7.69, 95%CI 1.92 to 30.70) and improvement in dysp-
noea (OR of 3.33, 95%CI 1.17 to 9.43). There was no difference
between groups for the clinical parameters of cough and wheeze.
Although the Martinez 2006 study described a significant differ-
ence between groups for the number of participants experienc-
ing reduced cough, we found no difference between groups when
ITT analyses was performed. Also as the methodology of subjec-
tive cough measures was not a validated method, this data is not
displayed as a forest plot. The data from Elborn 1992 though not
included in the final analysis reported that the ICS group had a
significant improvement in cough (p=0.02) but not wheeze and
dyspnoea. None of the other studies reported these clinical out-
comes.
Figure 1. Forest plot of comparison: 1 Stable State Bronchiectasis (6 months or less), outcome: 1.1 Clinical
severity indices.
2. Lung Function indices (Outcome 1.2, Figure 2 ) : Data from 3
studies (Joshi 2004;Martinez 2006; Tsang 1998) were included in
thismeta-analysis. In viewof clinically significant differences in the
baseline values between the two groups in one of the study (Tsang
1998), a change from baseline was taken as the outcome variable.
Though clinically small, the lung function indices of FEV1 and
FVC showed an improvement in the inhaled steroid group. Elborn
1992 also reported an improvement in the FEV1 in the ICS group
compared to the placebo group (P=0.03) but not in FVC.
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Figure 2. Forest plot of comparison: 1 Stable State Bronchiectasis (6 months or less), outcome: 1.2 Lung
function indices.
For FEV1 (end study minus baseline values) (Outcome 1.2.1), the
pooled data showed an improvement between the groups; MD
(fixed) = 0.09 (95% CI 0.03 - 0.15) and there was no significant
heterogeneity between studies.
For FVC (end study minus baseline values) (Outcome 1.2.2), there
was again small improvement in the ICS group;MD (fixed) = 0.09
(95% CI 0.02 - 0.16) with no significant heterogeneity between
studies.
For both FEV1 and FVC, when the Martinez study was excluded
(no placebo in this study), there was no longer any difference
between groups although the trend remained favouring the ICS
group.
ForPeak flow (end studyminus baseline values) (Outcome 1.2.3) data
was only available from 2 studies (Joshi 2004; Tsang 1998) which
showed a MD (fixed) = 26.23 (95% CI -5.84 to 58.31). Tsang
1998 showed a significant improvement in PEFR from baseline
values in the ICS group but the combined data was not statistically
significant.
Inhaled corticosteroids showed a (non significant) trend towards
improving the following outcomes: DLCO (MD (fixed) = 2.65
(95% CI -2.39 to 7.68) ), TLC (MD (fixed) = 2.55 (95% CI -
2.39 to 7.49)) and RV (MD (fixed) = -2.43 (95% CI -19.41 to
14.55)).
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3. Exacerbations (Outcome 1.3) : Data on average number of ex-
acerbation per subject was available fromonly one study (Martinez
2006) which showed no difference between the two groups (MD
(fixed) = 0.09 (95%CI -0.61 to 0.79)). In Tsang 1998, one patient
in the fluticasone group experienced an exacerbation compared
with three patients in the placebo group.
4. Sputum and biomarkers characteristics (Outcome 1.4):
a) Sputum volume per day (Outcome 1.4.1): Martinez 2006 was
the only study included in this analysis which showed a trend
towards reduction in the sputum volume with a MD (fixed) of -
8.30 [95% CI -16.55 to -0.05]. The data on sputum volume and
sputum inflammatory markers fromTsang 1998 was not included
in the final analysis due to clinically significant differences in the
baseline value between the two groups. Elborn 1992 also described
a significant improvement in the 24 hour sputum volume in the
ICS group (P =0.003). The other studies did not include this as
an outcome variable.
b) FeNO at 24 weeks (Outcome 1.4.2): Tsang 2004 showed no
change in the FeNO between the two groups at 24 weeks with a
MD (fixed) of 3 [95% CI -4.17 to 10.17]
The data on density of total bacteria, commensal bacteria and
Pseudomonas aeruginosa in sputum, though not included in the
final analysis, showed an increasing trend after 4 week therapy
with inhaled steroids. (Tsang 1998)
Stable state long term (> 6 months) outcomes (Comparison
2)
Data from Tsang 2004 and Tsang 2005 were included in the long
term stable state analysis though Tsang 2004 had only FeNO as
the outcome variable.
1. Clinical severity indices - No data was included for the clinical
parameters from the two studies (Tsang 2004 & Tsang 2005) of
more than 6 month duration.
2. Lung Function indices (Outcome 2.1):
For FEV1 % predicted (end study minus baseline values) (Outcome
2.1.1), data from the single studyTsang 2005 showednodifference
between the two groups; MD (fixed) = 0.30 (95% CI -17.43 to
18.03).
For FVC % predicted (end study minus baseline values) (Outcome
2.1.2), data from the single studyTsang 2005 showednodifference
between the two groups; MD (fixed) = -0.90 (95% CI -14.59 to
12.79).
3. Exacerbations (Outcome 2.2) : Tsang 2005 showed a non sig-
nificant reduction in the average number exacerbations per person
in the ICS group; MD (fixed) = -0.49 (95% CI -1.49 to 0.51).
4. Sputum and biomarker characteristics (Outcome 2.3):
a) Sputum volume per day : As an overall effect, ICS had no effect on
the 24 hour sputum volume when given for a period of 52 weeks
though the data for this outcome was not included in the analysis
because onlymedian and interquartile range were available and the
data was very skewed. As a subgroup analysis, Tsang 2005 report
a significant improvement in the amount of sputum volume/ day
in the subgroup of patients with sputum volume < 30 ml/ day,
exacerbation frequency <= 2/year, and sputum purulence score
score >5 (Data not available).
b) Sputum purulence score (Outcome 2.3.1): Sputum purulence was
scored as 0,1,2,3,4,5,6,7 or 8 (absence of, completely transparent,
almost transparent, translucent but colourless, opaque and milky
white grey, pale green, moderately green, and dark green sputum,
respectively) inTsang 2005. After 52weeks, therewas nodifference
in the purulence scores between the ICS and placebo group; MD
(fixed) = 0.2 ( 95% CI -0.94 to 1.34)
c) FeNO at 52 weeks (Outcome 2.3.2): Tsang 2004 showed no
change in the FeNO between the two groups at 52 weeks with a
MD (fixed) of -1.20 [95% CI -6.82 to 4.42]
Sensitivity analysis
As mentioned in comparisons 1 , removing the study with a poor
quality score (no placebo) altered the results for FEV1 and FVC
from being significant to non significant between the ICS and
control groups. On replacing the data from the fluticasone 1000µg
arm of Martinez 2006 with the 500µg data in the meta-analysis,
improvement in FEV1 still favoured the ICS group with a mean
difference (fixed) of 0.06 (95% CI 0.01, 0.10) though the effect
was less, whereas the effect of ICS became non significant for the
parameter of FVC (mean difference of 0.05, 95% CI -0.03, 0.12).
For the clinical data, the difference between the groups was still
significant (favouring ICS group) for number of subjects without
sputum volume reduction of >50% (OR of 0.19, 95%CI 0.05
to 0.79) though the variable of amount of sputum became non
significant with MD (fixed) = -5.7 (95% CI -14.9, 3.5). For the
outcomes of wheeze (OR of 0.65, 95%CI 0.22, 1.87) and cough
(OR of 0.59, 95%CI 0.21, 1.62), there was still no difference
between the groups. For the outcome of dyspnoea, actual data was
not provided for the 500µg arm but the authors mentioned that
there was no difference between groups. Hence it is assumed that
the significant effect present for the 1000µg/day group (outcome
1.1.4) was no longer present for the 500µg/day group. Also, there
was no change (i.e. no difference between groups) in the other
outcome variables (diffusion capacity, residual volume, total lung
capacity and exacerbation frequency)..
Analysis using random effects did not alter the significance of any
of the outcomes. None of the other planned sensitivity analysis
were relevant.
D I S C U S S I O N
The meta-analysis based on six studies involving 303 adults has
shown that use of high dose inhaled corticosteroids in patients with
non CF bronchiectasis leads to a statistically significant though
clinicallyminor improvement in the lung function indices of FEV1
and FVC but not for peak flow. However when the study that
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was not placebo-controlled was excluded, there was no significant
difference between groups in FEV1 or FVC. Also there was no
difference between groups for the other outcomes (exacerbations,
sputum volume, clinical symptoms and FeNO).
The three studies (Joshi 2004; Martinez 2006; Tsang 1998) in-
cluded in the short term effect of inhaled steroids in bronchiectasis
showed a clinically small benefit of ICS on lung function param-
eters of FEV1 and FVC. Two of the studies reported no signifi-
cant difference between groups and the major contribution with
a positive effect was that from Martinez 2006. Thus not surpris-
ingly when Martinez’s study was excluded based on quality (no
placebo), the groups no longer differed. Also there was no dif-
ference between groups for PEFR, diffusion capacity and TLC.
Nevertheless, Elborn 1992 data which could not be included in
the meta-analysis showed a significant improvement in the FEV1
as well as the 24 hour sputum volume in the ICS group compared
to placebo group.
Data on the short term effect of ICS on clinical parameters of
cough, wheeze, dyspnoea and sputum volume was available only
from one study (Martinez 2006). This showed a significant im-
provement in dyspnoea and sputum volume for the higher dose of
fluticasone (1000µg/day) compared to the control group The lack
of a placebo arm in this study makes assessment of these outcomes
biased. The effect was also lost when data from 1000ug/day flu-
ticasone was substituted by that for 500µg/day. Data on sputum
volume from Tsang 1998 was not included in the analysis in view
of clinically significant difference in the baseline values. Martinez
2006 showed a significant improvement in the quality of life score
in the ICS group using the St George’s Respiratory Questionnaire
but was not included in the final analysis since it encompassed all
the symptoms already included in the analysis.
Recurrent acute pulmonary exacerbations form part of the disease
progression in patients with bronchiectasis andmany of these exac-
erbations require hospital admission. Recurrent exacerbations not
only lead to progressive deterioration of lung functions (Ellerman
1997) but are also one of the strong predictors of poor quality of
life in bronchiectasis (Wilson 1997). In this review, short term use
of ICS did not significantly influence frequency of exacerbations .
Prolonged ICS administration also did not significantly influence
exacerbation frequency (Tsang 2005).This becomes more relevant
with the fact that ICS actually increased the bacterial density in
the airways (Tsang 1998) and most exacerbations in bronchiec-
tasis are likely of infective in origin. Though exacerbation was
defined in a similar manner in all three studies, its definition in
bronchiectasis, specially paediatric bronchiectasis, is not standard-
ized (Chang 2008). For further research into prevention and treat-
ment of bronchiectasis exacerbation to be useful, we need a con-
sensus on the definition of exacerbation.
Administration of inhaled steroids for a longer duration (Tsang
2004; Tsang 2005) significantly increased the number of subjects
who had a more than 20% reduction in the 24 hour sputum vol-
ume but did not have any beneficial effect in the other clinical
or spirometric parameters. This lack of effect again suggests that
infection and not pure inflammation, is probably the more rele-
vant underlying pathogenic mechanism of disease progression in
bronchiectasis.
Persistent inflammation plays a role in deterioration of lung func-
tion in bronchiectasis (Ip 1993). Studies in adults with CF suggest
that ICS treatment improves bronchial hyper-responsiveness and
spirometric parameters (Van Haren 1995). Thus it is theoretically
possible that ICSmay improve the lung functions and with it clin-
ical parameters in non CF bronchiectasis as well. However this
review has shown that any benefit from ICS is inconsistent. How-
ever given the increased presence of airway hyper-responsiveness
in patients with non CF bronchiectasis, it is possible that ICS may
have a role in this subgroup.
Moreover, even in CF, the clinical benefits of ICS have been diffi-
cult to demonstrate. A Cochrane review of ICS in CF concluded
that there is insufficient evidence to determine if they are benefi-
cial or harmful (Balfour-Lynn 2000). In a large prospective, mul-
ticenter study, withdrawal of inhaled corticosteroids for 6 months
was not associated with significant worsening of CF lung disease
(Balfour 2006). Patients in whom steroids were discontinued did
not have a change in lung function over time, an increased need
for oral or intravenous antibiotics, or a shorter time to pulmonary
exacerbation (Balfour 2006).
Nearly 50% of adults with COPD have bronchiectasis (Chang
2008). A recent Cochrane review (Yang 2007) concluded that ICS
administration reduce the rate of exacerbations as well as the rate of
decline in quality of life in patients with stable state COPD. As the
Martinez 2006 study included subjects who were smokers, there
is a possibility that some of these subjects had COPD and this
may influence the positive findings in that study. It also indicates
that COPD associated bronchiectasis may respond differently to
treatment modalities when compared to bronchiectasis associated
with other causes.
Also, the beneficial effect if any of long term administration of
high dose ICS has to be weighed against the potential adverse
effects associated with it. High dose ICS use is associated with
adverse events in children and adults that range from mild events
(candidiasis) to serious events (pneumonia, adrenal insufficiency,
osteoporosis, cataracts), Sobieraj 2008. Martinez 2006 reported
dry mouth, local irritation and transient dysphonia as the most
common adverse effects. None of the other studies reported any
adverse effects.
Limitations of the Review
This systematic review is limited to 6 adult studies with variable
designs, variable doses and length of study. Also data extraction
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was limited to only one to 4 studies for the outcomes examined.
The small sample size (max 101) for the meta-analysis is also a
significant limitation. The major contributor to the benefit of ICS
was from a non-placebo controlled study.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The present review indicates that there is insufficient evidence to
recommend the routine use of inhaled steroids in adults with stable
state bronchiectasis. The only study (Martinez 2006) that showed
a benefit was a non-placebo controlled trial. In a second study
benefit was found only with subgroup analysis and very high doses
were utilised. While a therapeutic trial may be justified in patients
with difficult to control symptoms, this has to be balanced with
adverse events especially if high doses are used. In bronchiectasis,
the adverse effect of ICS includes increased bacteria density and
thus surveillance sputum bacteriology is recommended. No rec-
ommendation can be made for the use of ICS in adults during an
acute exacerbation, or in children (for any state) as there were no
studies.
Implications for research
Further studies are required to examine the effect of inhaled cor-
ticosteroids on short and long term outcomes for children and
adults with non-CF bronchiectasis. Outcomes should include ex-
acerbations (rate and hospital admission), symptoms, quality of
life, lung function indices and inflammatory parameters and bac-
teriology. Studies are required in both stable state and during an
acute exacerbation state. A validated and standardised definition
of acute respiratory exacerbation is also required. Adult studies
should clearly differentiate co-existent COPD as the presence of
this may influence effect of ICS. A priori analysis for those with
AHR should also be defined since its presence may influence ICS
response.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Elborn 1992
Methods A prospective, double blind placebo controlled randomised cross over design with study
duration of 6 weeks
There were 5 patients who dropped out- unsure when these occurred. Two patients
declined to take part in second limb of study
No wash out period mentioned.
Participants Twenty patients (12 females, mean age 50 years, range 30-65) were studied with
bronchiectasis diagnosed by bronchogram in 18 and CT scan in two. No patient received
a course of antibiotics for at least 8 weeks prior to study
Exclusion: Patients with hypogammaglobulinaemia, CF, allergic bronchopulmonary as-
pergillosis (ABPA) or primary ciliary dyskinesia as well as those taking oral or inhaled
corticosteroids
Interventions Inhaled beclomethasone dipropionate 750 microgram BD by MDI or placebo for 6
weeks
Outcomes FEV1, FVC, morning and evening PEFR, 24 hour sputum amount collected weekly
from patients, visual analogue scale for cough, wheeze and dyspnoea recorded on a diary
card and on a 75 mm line (higher value better)
Notes Cross over design with no wash out period. Separate results of first arm not available.
Data not included in analysis
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “Patients were randomised to take
beclomethasone dipropionate”
Comment: Probably done.
Allocation concealment? Unclear Nomention how randomisation was done.
Blinding?
All outcomes
Yes Quote: “double-blinded” & “matched
placebo”
Incomplete outcome data addressed?
All outcomes
No There were 5 patients who dropped out-
unsure when these occurred. Two patients
declined to take part in second limb of
study
Free of selective reporting? Yes No suggestion that selective reporting may
have been done.
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Elborn 1992 (Continued)
Free of other bias? No Cross over design with no wash out period.
Separate results of first arm not available
Joshi 2004
Methods Randomized double blind placebo controlled cross over study with study duration of 4
weeks
Two week washout period between cross over.
Details of drop outs not clear.
Participants 20 patients (9 females) age range 15-60 years were prospectively enrolled. All patients
treated with oral salbutamol 2 mg four times daily and oral theophylline 200 mg four
times daily throughout the trial period
14 patients had unilateral disease and 6 had bilateral disease
Inclusion: Bronchiectasis confirmed by HRCT chest in stable state (no exacerbation
in previous 1 month) demonstrating significant post bronchodilator response (> 12%
change) on spirometry
Exclusion: Atopy, bronchial asthma or smoking
Interventions Inhaled beclomethasone 800 microgram/day in two divided doses by MDI or placebo
for 4 weeks
Outcomes FVC, FEV1 and PEFR at 4 weeks and 10 weeks.
Notes SD calculated from P value. Only first arm of the study before cross over used in analysis.
Additional information provided by the authors
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “patientswere randomised in a dou-
ble blind manner”. Comment: Probably
done
Allocation concealment? Unclear Nomention how randomisation was done.
Blinding?
All outcomes
Yes Quote: “patientswere randomised in a dou-
ble blind manner”. Comment: Probably
done
Incomplete outcome data addressed?
All outcomes
Unclear No mention of drop outs.
Free of selective reporting? Yes No suggestion that selective reporting may
have been done.
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Joshi 2004 (Continued)
Free of other bias? No Inclusion of patients who had a signifi-
cant post bronchodilator response biased
the study in favour of response to ICS
since those with positive bronchodilator re-
sponse are more likely to improve with ICS
due to the asthma like reversibility in their
airway
Martinez 2006
Methods Randomized (stratified for prior smoking habit in pack year), double blind (only for
dose of steroid) non placebo controlled prospective trial with study duration 6 months
Participants Of the 132 patients initially included in the study, 39 were excluded prior to randomisa-
tion (23 had high probability of asthma, 4 did not give consent, 1 had Down’s syndrome
and 3 each had psychiatric disorder, systemic steroids and had disease of significant sever-
ity). 93 patients enrolled in the study
7 drop outs during the study, 3 from the no steroid group and 2 each from the 500 µg
and 1000µg group. Study completed in 86 patients
No steroid group n = 28: mean age 70.9 (SD 6.1), 17 males. 500 µg/day fluticasone
group n=29: mean age 66.4 (SD 12.6), 18 males. 1000 µg/day group n=29: mean age
70.9 (SD 6), 21 males
Inclusion: All patients with HRCT diagnosed bronchiectasis diagnosed between 1993
and June 2003 in Requena General Hospital. The patients were required to be free from
acute exacerbation for at least 4 weeks
Exclusion: Patients with asthma, CF and on whom inhaled steroids could not be stopped
Interventions Inhaled fluticasone 500 µg BD by MDI vs. 250 µg fluticasone BD vs. no treatment for
6 months
Outcomes Baseline data collection started 6months prior to randomisation. During this period data
prospectively collected on number of acute exacerbations, antibiotic use and hospital
admissions
FEV1, FVC, TLC, RV and diffusion capacity measured few days prior to randomisation
During randomisation visit, information collected on dyspnoea score, daily sputum
production (average of sputum produced over 3 days); cough and need for short acting
bronchodilator in the 1 month prior to randomisation, and health-related quality of life
(HRQol) using the validated Spanish versionof the St.GeorgeRespiratoryQuestionnaire
(SGRQ)
After randomisation, TLC, RV and diffusion capacity analysed again after 6 months.
HRQol assessment at 3 and 6 months and all other tests at 1, 3 and 6 months
>4 point change in SGRQ considered significant. > 1 point change is dyspnoea score
considered significant
Notes All comparisons made only between no steroids and 500 µg BD group. Additional
information provided by the authors
Risk of bias
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Martinez 2006 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “A prospective, randomised...”
Comment: Probably done.
Allocation concealment? Unclear Nomention how randomisation was done.
Blinding?
All outcomes
No Quote: “The study was conducted on a
double blind basis regarding the effective
inhalatory steroid dose administered (500
vs. 1000 µg/day), but not as relates to the
administration or not of steroid treatment
(i.e. 0 vs. 500 or 1000 µg/day).”
Comment: No blinding for the two groups
assessed by us (0 vs. 1000 µg/day)
Incomplete outcome data addressed?
All outcomes
No The patient characteristics and outcome
data of those excluded or dropped out not
described and not compared with those in-
cluded for analysis
Free of selective reporting? No Information onTLC, RV andDLCOgath-
ered but not reported.
Free of other bias? No Intention to treat analysis not done.
Tsang 1998
Methods Randomized double blind placebo controlled prospective trial with study duration of 4
weeks
There were no drop outs.
Participants 24 patients (mean age 51 years, 12 F) with HRCT proven bronchiectasis
Fluticasone group: n=12, 6 females, age: mean 43 (SD 11). Placebo group: n=12, 8
females, age: mean 56.8 (SD 11)
Inclusion: Daily sputum > 10ml, absence of asthma or other unstable systemic disease;
and “steady state” bronchiectasis (< 10% alteration of 24 hour sputum volume, FEV1
and FVC).
Exclusion: Unreliable clinic attendance, known adverse reaction to fluticasone, regular
use of ICS and asthma
Interventions Inhaled Fluticasone 500 µg BD by accuhaler or placebo for 4 weeks
Outcomes FEV1, FVC, TLC, RV, diffusion capacity, PEFR, 24 h sputum volume (mean of three
days), sputum leukocyte density, bacterial densities and concentrations of interleukin
(IL)1B, IL 8, tumour necrosis factor (TNF) alpha and leukotriene B4 were all measured
at the time of randomization and at 4 weeks
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Tsang 1998 (Continued)
Notes SD estimated from 95% confidence intervals. Change from baseline used instead of
post treatment values in view of clinically significant differences in the baseline values
for fluticasone and placebo group. Values for number of females different in abstract
compared with the table
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “randomly assigned into receiving
either fluticasone (500 µg twice daily) or
otherwise identical placebo”
Comment: Probably done.
Allocation concealment? Unclear Nomention how randomization was done.
Blinding?
All outcomes
Yes Quote: “performed a double blind, placebo
controlled study”. Comment: Probably
done
Incomplete outcome data addressed?
All outcomes
Yes There were no drop outs.
Free of selective reporting? Yes No suggestion that selective reporting may
have been done.
Free of other bias? No The baseline values for lung functions, spu-
tum amount and sputum inflammatory
markers were significantly different clini-
cally in and thus were subject to bias
Tsang 2004
Methods Randomized double blind prospective placebo controlled trial with study duration of 52
weeks
There were no drop outs.
Participants 60 patients (mean age 56.4 years, 38 F) with HRCT proven bronchiectasis
Fluticasone group: n=30, age: mean 56.1 (SD 14). Placebo group: n=30, age: mean 56.
7 (SD 11.3)
16 were Pseudomonas colonized and 44 were not.
Inclusion: Absence of asthma or other unstable systemic disease; and “steady state”
bronchiectasis (< 20% alteration of 24 hour sputum volume, FEV1 and FVC) and
absence of deterioration in respiratory symptoms at baseline visit
Exclusion: Unreliable clinic attendance, known adverse reaction to fluticasone and
asthma
Interventions Inhaled fluticasone 500 microgram BD by accuhaler or placebo for 52 weeks
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Tsang 2004 (Continued)
Outcomes The patients were followed up at -2, -1, 0, 4, 12, 24, 36, 48 and 52 weeks after com-
mencement of therapy for measurement of fractional exhaled nitric oxide (FeNO)
Notes SD calculated from interquartile (IQ) range. Medians used instead of means. Data at 24
weeks and 52 weeks included in the analysis
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “before randomization to receive
fluticasone (500µg twice daily) or identical
placebo”
Comment: Probably done.
Allocation concealment? Unclear Nomention how randomization was done.
Blinding?
All outcomes
Yes Quote: “performed a double blind, placebo
controlled study”. Comment: Probably
done
Incomplete outcome data addressed?
All outcomes
Yes There were no drop outs.
Free of selective reporting? Yes No suggestion that selective reporting may
have been done.
Free of other bias? No Baseline value of the 2 groups were signifi-
cantly different.
Tsang 2005
Methods Randomized double blind prospective placebo controlled trial with study duration of 52
weeks
5 dropouts in the placebo arm (1 at 4 weeks, 3 at 24 weeks and 1 at 52 weeks) and 8
dropouts in the fluticasone arm (2 at 4 weeks and 1 each at 6, 22, 32, 36, 50 and 52
weeks)
Participants 89 patients recruited. 3 patients withdrew. 86 patients (57 females, mean age 58.5 years)
with HRCT proven bronchiectasis randomized between fluticasone and placebo
Fluticasone group: n=43, 23 females, age: mean 57.7 (SD 14.4). Placebo group: n=43,
34 females, age: mean 59.2 (SD 14.2)
23 were Pseudomonas colonized.
Inclusion: Absence of asthma or other unstable systemic disease; and “steady state”
bronchiectasis (< 20% alteration of 24 hour sputum volume, FEV1 and FVC) and
absence of deterioration in respiratory symptoms at baseline visit
Exclusion: Unreliable clinic attendance, known adverse reaction to fluticasone or
quinolones and regular usage of ICS
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Tsang 2005 (Continued)
Interventions Inhaled fluticasone 500 microgram BD by accuhaler device or matched placebo for 52
weeks
Outcomes The patients were followed up at -2, -1, 0, 4, 12, 24, 36, 48 and 52 weeks after com-
mencement of therapy
Primary outcomes were: 24 hour sputum volume (mean of 3 days) and cumulative
exacerbation frequency
Secondary outcomes were: Sputum purulence score, FEV1%, and FVC %.
Improvement or deterioration was defined as >20% change from baseline
Notes SD calculated from P value for sputum volume and exacerbation frequency and from
confidence interval for the rest
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “randomisation (block of 4)”.
Comment: Probably done
Allocation concealment? No Quote: “randomisation (block of 4)”.
Comment: Probably not done
Blinding?
All outcomes
Yes Quote: “double blind, placebo controlled
study”.
Incomplete outcome data addressed?
All outcomes
No Data of drop outs not compared to those
included in analysis
Free of selective reporting? Yes No suggestion that selective reporting may
have been done.
Free of other bias? No Significant differences at the baseline on
clinical features of “Cough” and “Dyspnea”
between the two groups to allow for post
treatment comparison
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ghosh 2002 Study compared effects of inhaled budesonide with inhaled ipratropium and not placebo
Monton 1999 Study included patients with pneumonia and not bronchiectasis. Used systemic steroids not inhaled
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(Continued)
ONeil 2004 Study not a RCT. Studies subjective benefits of inhaler therapy including both ICS and bronchodilators
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D A T A A N D A N A L Y S E S
Comparison 1. Stable State Bronchiectasis (6 months or less)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical severity indices 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Number of subjects with
regular wheeze
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.2 Number of subjects
without sputum reduction of
>50%
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.3 Number of subjects with
no improvement in dyspnoea
score > 1 (min important
difference)
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2 Lung function indices 3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 FEV1 (in L, end study
minus baseline values)
3 101 Mean Difference (IV, Fixed, 95% CI) 0.09 [0.03, 0.15]
2.2 FVC (in L, end study
minus baseline values)
3 101 Mean Difference (IV, Fixed, 95% CI) 0.09 [0.02, 0.16]
2.3 Peak flow (L/min, end
study minus baseline values)
2 44 Mean Difference (IV, Fixed, 95% CI) 26.23 [-5.84, 58.31]
2.4 Diffusion capacity
%predicted (end of study)
2 81 Mean Difference (IV, Fixed, 95% CI) 2.65 [-2.39, 7.68]
2.5 RV %predicted (end of
study values)
2 63 Mean Difference (IV, Fixed, 95% CI) -2.43 [-19.41, 14.
55]
2.6 TLC % predicted (end of
study values)
2 81 Mean Difference (IV, Fixed, 95% CI) 2.55 [-2.39, 7.49]
3 Average number of exacerbations
per subject
1 57 Mean Difference (IV, Fixed, 95% CI) 0.09 [-0.61, 0.79]
4 Sputum and biomarkers
characteristics
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Sputum volume or weight
(per day)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
4.2 FeNO (ppb) at 24 weeks 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
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Comparison 2. Stable State (>6 months)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Lung Function Indices 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 FEV1% predicted (end
study minus baseline values)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
1.2 FVC % predicted (end
study minus baseline values)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
2 Average exacerbation per subject 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Sputum and biomarker
characteristics
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Sputum purulence score 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
3.2 FeNO (ppb) at 52 weeks 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
WH A T ’ S N E W
Last assessed as up-to-date: 26 October 2010.
Date Event Description
27 October 2010 New search has been performed Literature search run, no new studies identified.
H I S T O R Y
Protocol first published: Issue 2, 1997
Review first published: Issue 2, 1999
Date Event Description
15 August 2008 New citation required and conclusions have changed Aug 2008: New author team, protocol changed and
previous included studies data amended, new studies
added, conclusions changed
5 May 2008 Amended Converted to new review format.
10 September 2007 New search has been performed New literature search performed
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol, long term effect was defined as that measured at more than 12 months duration. This was changed to more than
6 months duration in the final review. Data from Martinez 2006 was included in the review though the comparison between the
untreated and the ICS groups were not blinded. Also, for the clinical severity assessment in the Martinez 2006 study, outcome variables
of sputum reduction > 50% and dyspnoea score improvement > 1 were used post hoc since these were the ones available from the study.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Inhalation; Adrenal Cortex Hormones [∗administration & dosage]; Androstadienes [administration & dosage]; Anti-
Bacterial Agents [administration & dosage]; Beclomethasone [administration & dosage]; Bronchiectasis [∗drug therapy]; Randomized
Controlled Trials as Topic; Respiratory Function Tests
MeSH check words
Adult; Humans
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